Logo image of NYXH

NYXOAH SA (NYXH) Stock Fundamental Analysis

NASDAQ:NYXH - Nasdaq - BE0974358906 - Common Stock - Currency: USD

7.97  +0.04 (+0.5%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NYXH. NYXH was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NYXH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NYXH has reported negative net income.
In the past year NYXH has reported a negative cash flow from operations.
NYXH had negative earnings in each of the past 5 years.
NYXH had a negative operating cash flow in each of the past 5 years.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of NYXH (-51.30%) is worse than 66.84% of its industry peers.
NYXH has a Return On Equity (-75.09%) which is in line with its industry peers.
Industry RankSector Rank
ROA -51.3%
ROE -75.09%
ROIC N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

NYXH has a better Gross Margin (65.54%) than 68.98% of its industry peers.
NYXH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
NYXH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NYXH has more shares outstanding
Compared to 1 year ago, NYXH has a worse debt to assets ratio.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

NYXH has an Altman-Z score of 0.07. This is a bad value and indicates that NYXH is not financially healthy and even has some risk of bankruptcy.
NYXH's Altman-Z score of 0.07 is in line compared to the rest of the industry. NYXH outperforms 44.38% of its industry peers.
NYXH has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NYXH (0.22) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 0.07
ROIC/WACCN/A
WACC7.47%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

NYXH has a Current Ratio of 3.59. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
NYXH has a Current ratio of 3.59. This is in the better half of the industry: NYXH outperforms 63.10% of its industry peers.
NYXH has a Quick Ratio of 3.35. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NYXH (3.35) is better than 67.38% of its industry peers.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.35
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.63%.
Looking at the last year, NYXH shows a very negative growth in Revenue. The Revenue has decreased by -14.90% in the last year.
The Revenue has been growing by 74.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.1%
Revenue 1Y (TTM)-14.9%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%-12.86%

3.2 Future

NYXH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.61% yearly.
NYXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 135.57% yearly.
EPS Next Y-3.82%
EPS Next 2Y5.42%
EPS Next 3Y10.61%
EPS Next 5YN/A
Revenue Next Year257.85%
Revenue Next 2Y229.99%
Revenue Next 3Y171.07%
Revenue Next 5Y135.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.42%
EPS Next 3Y10.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYXOAH SA

NASDAQ:NYXH (7/16/2025, 4:30:02 PM)

7.97

+0.04 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners25.49%
Inst Owner Change0%
Ins Owners22.07%
Ins Owner ChangeN/A
Market Cap298.32M
Analysts81.43
Price Target14.62 (83.44%)
Short Float %0.57%
Short Ratio1.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.03%
Min EPS beat(2)-22.16%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)-5.72%
Min EPS beat(4)-22.16%
Max EPS beat(4)2.11%
EPS beat(8)5
Avg EPS beat(8)1.43%
EPS beat(12)7
Avg EPS beat(12)-4.08%
EPS beat(16)8
Avg EPS beat(16)-5.04%
Revenue beat(2)0
Avg Revenue beat(2)-37.56%
Min Revenue beat(2)-38.43%
Max Revenue beat(2)-36.69%
Revenue beat(4)0
Avg Revenue beat(4)-35.28%
Min Revenue beat(4)-55.92%
Max Revenue beat(4)-10.09%
Revenue beat(8)1
Avg Revenue beat(8)-22.43%
Revenue beat(12)1
Avg Revenue beat(12)-33.85%
Revenue beat(16)2
Avg Revenue beat(16)-35.91%
PT rev (1m)1.21%
PT rev (3m)-7.27%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)-17.83%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)-47.19%
Revenue NQ rev (3m)-52.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-29.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 58.6
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 6.11
EV/EBITDA N/A
EPS(TTM)-2.32
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0.14
BVpS2.89
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.3%
ROE -75.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.54%
FCFM N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.9%
Cap/Sales 25.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.35
Altman-Z 0.07
F-Score2
WACC7.47%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.1%
EPS Next Y-3.82%
EPS Next 2Y5.42%
EPS Next 3Y10.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.9%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%-12.86%
Revenue Next Year257.85%
Revenue Next 2Y229.99%
Revenue Next 3Y171.07%
Revenue Next 5Y135.57%
EBIT growth 1Y-46.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.8%
EBIT Next 3Y1.88%
EBIT Next 5Y11.04%
FCF growth 1Y-61.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.47%
OCF growth 3YN/A
OCF growth 5YN/A